FacultyFaculty/Author Profile
Stanton J. Lovenworth

Stanton J. Lovenworth

O'Melveny & Myers LLP

New York, NY, USA

Stanton J. Lovenworth is a Senior Counsel in O’Melveny’s New York office and a member of the Health Care and Life Sciences Practice.  Stan has more than three decades of experience representing leading and emerging companies in intellectual property transactions, particularly in the biopharmaceutical sector, including:  mergers and acquisitions; joint ventures, collaborations and strategic alliances; divestitures, and technology licensing; research, development, clinical trial, co-development, co-promotion, and supply and manufacturing agreements; “spin-outs” and investment transactions.

Stan has been repeatedly recognized by The Legal 500 US as a leading practitioner in the areas of life sciences, trademark, advertising and marketing, and was a winner of a 2013 Distinguished Legal Writing Award from the Burton Awards for Legal Achievement.  He was the Global Chair of the Life Sciences Practice and Global Co-Chair of the IP Transactions practice at his former AmLaw 50 firm.

Illustrative Licensing and Collaboration Experience

  • Aaron Diamond AIDS Research Center - Licensing and research arrangement for AIDS vaccines with International AIDS Vaccine Initiative
  • Aptalis Pharmaceuticals - License, commercialization and supply arrangements with ProStrakan for ProStrakan’s Rectiv®
  • GenVec - Termination of development alliance with Pfizer
  • Illumina - Strategic collaboration with Invitrogen, Inc.
  • Intermune - Termination of clinical research and supply arrangements with Boehringer Ingelheim Austria
  • MedImmune - Sale to MGI Pharma of intellectual property assets related to Hexalen® and related arrangements
  • MedImmune - Purchase of preferred stock of Genaera Corporation and related research, development and commercialization collaboration
  • Novartis - Research, development, commercialization, and manufacturing collaboration with Idenix relating to HBV, HCV and HIV compounds
  • Novartis - Licensing and supply arrangements with GlaxoSmithKline in connection with Famvir®
  • Novartis - Licensing arrangement with Alnylam Pharmaceuticals in connection with siRNA technology
  • Novartis - Licensing arrangements with Alnylam in connection with siRNA compounds to fight pandemic influenza, including bird flu
  • Novartis - Out-licensing arrangements related to various discontinued research programs of gene therapy and related equity arrangements
  • Progenics Pharmaceuticals - Acquisition of an international portfolio of patent rights
  • Progenics Pharmaceuticals - Worldwide co-development and co-promotion agreement with Wyeth in connection with Progenics’ methylnaltrexone (Relistor®) technology
  • Progenics Pharmaceuticals - Termination of Co-development agreement with Wyeth
  • Progenics Pharmaceuticals - Co-development and co-promotion agreement with Ono Pharmaceuticals in connection with Relistor® in Japan
  • Progenics Pharmaceuticals - Worldwide (ex-Japan) co-development and commercialization agreement with Salix Pharmaceuticals in connection with Relistor®
  • Progenics Pharmaceuticals - Licensing and joint venture arrangements with EUSA Pharma (formerly Cytogen Corporation)
  • Wyeth - Co-promotion and supply arrangements with King Pharmaceuticals
  • Wyeth - License and sublicense agreement to and supply agreement with Barr Laboratories in connection with progestin, and sale to Barr Laboratories of Aygestin®, Diamox®, Zebeta® and Ziac® product lines
  • Other clients - Schering-Plough, Gilead Sciences, Eli Lilly, Fougera, King Pharmaceuticals, Actavis, Errant Gene Therapy, Mitsubishi Tanabe, Middlebrook Pharmaceuticals, StemPar Sciences


Columbia Law School, J.D. 1977: Harlan Fiske Stone Scholar
University of Paris, associated with Ecole Normale Supérieure, M.A., French Political History, 1974:  with High Honors
Haverford College, B.A., 1971:  magna cum laude; Phi Beta Kappa; History prize
New York University School of Law, additional studies in Intellectual Property L.L.M. program, 1993-1994
Cambridge University, additional studies in History Ph.D. program 1971-1974

Professional Activities

Admitted,  New York

Member,  American Bar Association, Intellectual Property Section; International Trademark Association; Licensing Executives’ Society

Author, “The New Biosimilar Era:  The Basics, the Landscape and the Future,” Bloomberg Life Sciences Report (September 2012), winner of a 2013 Distinguished Legal Writing Award from the Burton Awards for Legal Achievement.

Co-Author,  “The High Court’s Dangerous Reset on Gene Patent,” Law 360 (July 2013); “U.S. Supreme Court Hears Arguments in Bayh-Dole Act Case Pitting Rights of Individual Inventors Against Universities,” Bloomberg Law Reports (April 2011); “Patent Licensees: Beware Impact of Licensor Bankruptcy,” New York Law Journal (June 2010); American Origin Products (AOP): Protecting a Legacy (2010); “Update for Small Biotech and Pharmaceutical Companies,” Practical U.S./Domestic Tax Strategies (May 2010); “Protect Your IP Licensing Agreement,” Executive Counsel (November 2009); “Protecting Geographically Unique Products,” New York Law Journal (January 22, 2008); “Exit via the Pipeline: M&A Activity in the Pharmabiotech Sector,” Daily Deal (November 28, 2006); “Welcome to the World of Wiki and Linux: Enforcement of Copyright in Collaborative Works,” TMCnet (September 27, 2006); “The Research Tool Conundrum,” New York Law Journal (October 17, 2005); “Merck v. Integra: Its effect on Innovative Drug Discovery,” Bio-IT World (August 2, 2005); “The Third Thing: Defining Trade Dress After Wal-Mart v. Samara Brothers,” Legal Times (March 4, 2002); “Exploring the Boundaries of Co-Existing Trademarks,” New York Law Journal (January 15, 1999); “Planning For A New Age: Employee Ownership of Intellectual Property,” The Corporate Counselor (March 1996); “Protection of Well Known Trademarks in China,” New York Law Journal (August 21, 1995); “China Trade Accord May Protect Software Vendors,” The National Law Journal (June 5, 1995)

Speaker,  “Treatment of Intellectual Property Licenses in Bankruptcy, PLI Advanced Licensing-2013 (March 2013); “Patents in the Pharma World,” Global IP Conference (New Delhi, India, January 2012); “Protecting Geographical Indications in the United States,” AIPPI (Hyderabad, India, October 2011); “GI Challenges in the U.S.,” OriGIn (Washington, D.C., June 2010); “GI Challenges in the U.S.,” OriGIn (Geneva, Switzerland, February 2010); “GI Challenges in the U.S.,” OriGIn General Assembly (Teruel, Spain, June 2009); “Protecting Geographically Distinctive Products in the United States,” ABA IP Law Section (Washington, D.C., April 3, 2009); “Innovative Financing Techniques for Pharmas and Biotechs,” New York Biotechnology Association (New York, February 24, 2009); “Using Due Diligence to Identify and Minimize Risks,” ACI (New York, November 14, 2006); “Creative New Deal Structures,” BioNetwork 2006 (Laguna Beach, October 4, 2006); “Commercial and Ethical Issues in Pandemic Flu Collaboration” Licensing Executives Society (New York, September 13, 2006); “Biotech-Pharma Collaborations: The Fiduciary Duties You Owe to Your Collaboration Partners and How to Handle Them,” New York Biotechnology Association (New York, April 18, 2006); “Life Sciences IP Due Diligence,” ACI (New York, January 31 and June 27, 2006); “What You Should Know About Your Fiduciary Duties to Your Partners,” New York Biotechnology Association (New York, May 25, 2005); “When Equity Enters the Equation: Examining the Key Governance and Alliance Issues in Pharma/Biotech Deals,” BioBusiness 2004 (Geneva, January 28, 2004)

Honors,  The Legal 500 leading lawyer in trademark law (2007-2012); The Legal 500 leading lawyer in advertising and marketing (2010-11); The Legal 500 leading lawyer in life sciences (2011-12); named a “Super Lawyer” in a survey conducted by Law Politics Media Inc. and published in New York Magazine (2006-09; 2012); winner, 2013 Distinguished Legal Writing Award from the Burton Awards for Legal Achievement


  • twitter
  • LinkedIn
  • YouTube
  • RSS

All Contents Copyright © 1996-2019 Practising Law Institute. Continuing Legal Education since 1933.

© 2019 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.